Home Journals Articles Updates About
CN
image
收藏切换
Impacts of Inflation Reduction Act on drug spending in the United States
收藏切换
PDF
Zhi-ming HUANG1, Hong-jie CAO2, Jin-ping XIE1, Li-xin YAO3, Rong SHAO1
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(11) : 825 - 829
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(11): 825-829
• Policy and Management •
Impacts of Inflation Reduction Act on drug spending in the United States
Full
Zhi-ming HUANG1, Hong-jie CAO2, Jin-ping XIE1, Li-xin YAO3, Rong SHAO1
Affiliations
  • 1.Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing JIANGSU 211198, China
  • 2.National Institutes for Food and Drug Control, BEIJING 102629, China
  • 3.National Medical Products Administration Institute of Medical Economics, Guangzhou GUANGDONG 510080, China
Published: 2024-11-25 doi: 10.14109/j.cnki.xyylc.2024.11.05
Outline
收藏切换

The Inflation Reduction Act（IRA）took effect in the United States in 2022. For the first time, the IRA allows the federal government to negotiate prescription drug prices, requires pharmaceutical companies to pay rebates to Medicare when prices rise above the rate of inflation, caps patient out-of-pocket costs for Medicare Part D drugs and insulin products, continues the “safe harbor” policy, extends the advance premium tax credit policy, and expands the types of free vaccinations. The IRA has multiple impacts on Medicare drug spending, but it still faces structural pressure in terms of price control. It is suggested that China can continue to utilize the public welfare advantages of basic medical and healthcare services, improve the targeting and operability of relevant health policies,and protect innovation while controlling drug prices.

medical insurancel  /  fees, pharmaceutical  /  health policy  /  drug-price negotiations
Zhi-ming HUANG, Hong-jie CAO, Jin-ping XIE, Li-xin YAO, Rong SHAO. Impacts of Inflation Reduction Act on drug spending in the United States[J]. Chinese Journal of New Drugs and Clinical Remedies, 2024 , 43 (11) : 825 -829 . DOI: 10.14109/j.cnki.xyylc.2024.11.05
Appendix
Less
Year 2024 volume 43 Issue 11
PDF
109
53
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2024.11.05
  • Receive Date：2023-10-24
  • Online Date：2026-03-13
  • Published：2024-11-25
Article Data
Affiliations
History
  • Received：2023-10-24
  • Accepted：2024-06-28
Affiliations
    1.Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing JIANGSU 211198, China
    2.National Institutes for Food and Drug Control, BEIJING 102629, China
    3.National Medical Products Administration Institute of Medical Economics, Guangzhou GUANGDONG 510080, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.11.05
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House